Literature DB >> 12930375

T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy.

P F Fogarty1, M E Rick, W Zeng, A M Risitano, C E Dunbar, J B Bussel.   

Abstract

In recent years, a pathophysiological role for T cells in immune thrombocytopenia (ITP) has been established. We applied cDNA size distribution analysis of the T cell receptor (TCR) beta-variable (VB) complementarity-determining region 3 (CDR3) in order to investigate T cell repertoire diversity among immune thrombocytopenia patients who had either responded or not responded to splenectomy, and compared them to normal controls. ITP patients who had had a durable platelet response to splenectomy showed a mean 2.8 +/- 2.1 abnormal CDR3 size patterns per patient, similar to healthy volunteers (2.9 +/- 2.0 abnormal CDR3 size patterns). In contrast, patients unresponsive to splenectomy demonstrated evidence of significantly more clonal T cell expansions than patients who had responded to splenectomy or controls (11.3 +/- 3.3 abnormal CDR3 size patterns per patient; P < 0.001). Of the VB subfamilies analysed, VB3 and VB15 correlated with response or non-response to splenectomy, each demonstrating oligoclonality in non-responding patients (P < 0.05). These findings suggest that removal of the spleen may lead directly or indirectly to reductions in T cell clonal expansions in responders, or that the extent of T cell clonality impacts responsiveness to splenectomy in patients with ITP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930375      PMCID: PMC1808786          DOI: 10.1046/j.1365-2249.2003.02239.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura.

Authors:  M Kuwana; J Kaburaki; H Kitasato; M Kato; S Kawai; Y Kawakami; Y Ikeda
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

2.  Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura.

Authors:  Masataka Kuwana; Yutaka Kawakami; Yasuo Ikeda
Journal:  Blood       Date:  2002-08-22       Impact factor: 22.113

3.  The response to high-dose intravenous immunoglobulin or steroids is not predictive of outcome after splenectomy in adults with autoimmune thrombocytopenic purpura.

Authors:  M Ruivard; M T Caulier; J M Vantelon; O Tournilhac; A Schaeffer; B Godeau; P Bierling
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

4.  Quantitation of platelet-binding IgG produced in vitro by spleens from patients with idiopathic thrombocytopenic purpura.

Authors:  R McMillan; R L Longmire; R Yelenosky; R L Donnell; S Armstrong
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

5.  T cell antigen receptors in autoimmunity.

Authors:  D N Posnett; A Gottlieb; J B Bussel; S M Friedman; N Chiorazzi; Y Li; P Szabo; N R Farid; M A Robinson
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

Review 6.  Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients.

Authors:  J B Bussel
Journal:  Semin Oncol       Date:  2000-12       Impact factor: 4.929

7.  Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia.

Authors:  J W Semple; J Freedman
Journal:  Blood       Date:  1991-11-15       Impact factor: 22.113

8.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

9.  Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).

Authors:  Joseph Schwartz; Melissa D Leber; Shmuel Gillis; Austin Giunta; Amiram Eldor; James B Bussel
Journal:  Am J Hematol       Date:  2003-02       Impact factor: 10.047

10.  Platelet destruction in autoimmune thrombocytopenic purpura: kinetics and clearance of indium-111-labeled autologous platelets.

Authors:  J R Stratton; P J Ballem; T Gernsheimer; M Cerqueira; S J Slichter
Journal:  J Nucl Med       Date:  1989-05       Impact factor: 10.057

View more
  7 in total

Review 1.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 2.  Advances in immunopathogenesis of adult immune thrombocytopenia.

Authors:  Xinguang Liu; Yu Hou; Jun Peng
Journal:  Front Med       Date:  2013-11-21       Impact factor: 4.592

Review 3.  Pathophysiology and therapeutic options in primary immune thrombocytopenia.

Authors:  Roberto Stasi
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

4.  Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia.

Authors:  Haiyu Zhang; Bing M Zhang; Xiangqian Guo; Liwen Xu; Xiaoqing You; Robert B West; James B Bussel; James L Zehnder
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941

Review 5.  Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.

Authors:  Oriana Miltiadous; Ming Hou; James B Bussel
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

6.  Defective regulatory B-cell compartment in patients with immune thrombocytopenia.

Authors:  Xiaojuan Li; Hui Zhong; Weili Bao; Nayla Boulad; Jessie Evangelista; Muhammad Anis Haider; James Bussel; Karina Yazdanbakhsh
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

7.  Possible involvement of regulatory T cell abnormalities and variational usage of TCR repertoire in children with autoimmune neutropenia.

Authors:  S Goda; S Hayakawa; S Karakawa; S Okada; H Kawaguchi; M Kobayashi
Journal:  Clin Exp Immunol       Date:  2020-12-27       Impact factor: 5.732

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.